<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508389</url>
  </required_header>
  <id_info>
    <org_study_id>GT-201</org_study_id>
    <nct_id>NCT02508389</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered&#xD;
      prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and&#xD;
      severity of radiation induced oral mucositis in patients who have been diagnosed with locally&#xD;
      advanced, non-metastatic squamous cell carcinoma of the head and neck.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GT-201 is a randomized, double-blind, placebo-controlled, multi-center study conducted in the&#xD;
      U.S. to evaluate GC4419 administered via an intravenous line (IV) for the reduction of&#xD;
      incidence, duration, and severity of radiation induced oral mucositis in patients receiving&#xD;
      cisplatin plus intensity-modulated radiation therapy for post-operative, or definitive&#xD;
      treatment of locally advanced, non-metastatic squamous cell carcinoma of the head and neck,&#xD;
      limited to the oral cavity or oropharynx. Patients will be randomized equally to 1 of 3&#xD;
      treatment arms:&#xD;
&#xD;
      Arm A: 30 mg GC4419 per day (60 min IV infusion to complete within 60 minutes prior to IMRT),&#xD;
      concurrent with daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over&#xD;
      approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for&#xD;
      3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).&#xD;
&#xD;
      Arm B: 90 mg GC4419 per day (60 min IV infusion to complete within 60 minutes prior to IMRT),&#xD;
      concurrent with daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over&#xD;
      approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for&#xD;
      3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).&#xD;
&#xD;
      Arm C: Placebo daily (60 min IV infusion to complete within 60 minutes prior to IMRT),&#xD;
      concurrent with daily fractions of IMRT (2.0 - 2.2 Gy) to a total of 60 - 72 Gy over&#xD;
      approximately 7 weeks, plus cisplatin administered 80 - 100 mg/m2 once every three weeks for&#xD;
      3 doses or 30 - 40 mg/m2 once weekly for 6-7 doses (investigator's choice).&#xD;
&#xD;
      Planned radiation fields in all 3 arms must include at least two oral sites (buccal mucosa,&#xD;
      floor of mouth, tongue, soft palate) with each site receiving a dose of at least 50 Gy.&#xD;
&#xD;
      All patients will be assessed twice weekly for oral mucositis per WHO grading criteria until&#xD;
      the completion of IMRT, and once weekly thereafter (if necessary) for 8 weeks, or until oral&#xD;
      mucositis resolves to ≤ Grade 1.&#xD;
&#xD;
      Approximately 200 total to ensure that roughly 60 patients per arm receive study drug and&#xD;
      complete requirements for primary endpoint analysis, which is defined as patients receiving a&#xD;
      minimum cumulative dose of 60 Gy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 12, 2015</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria</measure>
    <time_frame>From start of Intensity-modulated radiation therapy (IMRT) through 8 weeks follow-up, an average of 15 weeks</time_frame>
    <description>Assessed from the first determination of ≥Grade 3 OM to the first instance of non-severe OM (≤Grade 2), without a subsequent instance of ≥Grade 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>First dose of IMRT through the completion of IMRT, estimated to be up to 7 weeks.</time_frame>
    <description>Number of participants with treatment emergent adverse events (TEAE) per arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience Severe OM</measure>
    <time_frame>Minimum of 60 Gy administered to tumor, approximately 30 IMRT fractions, which is estimated to be 6-7 weeks.</time_frame>
    <description>Number of participants who experience severe OM from the first IMRT fraction through the last IMRT fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Grade 4 OM From the First IMRT Fraction Through the Last IMRT Fraction</measure>
    <time_frame>First dose of IMRT through the completion of IMRT, estimated to be up to 6-7 weeks.</time_frame>
    <description>Number of Participants who experienced Grade 4 OM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of IMRT Fractions Delivered at Onset of Severe OM</measure>
    <time_frame>Onset of Severe OM, estimated to be between first dose of IMRT and 7 weeks.</time_frame>
    <description>Onset of severe OM: number of IMRT fractions delivered at onset of severe OM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Grade 4 Oral Mucocitis (OM) From the First IMRT Fraction Through the Last IMRT Fraction</measure>
    <time_frame>Onset of Grade 4 OM, estimated to be between first dose of IMRT and 7 weeks.</time_frame>
    <description>Number of Participants who experienced Grade 4 OM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths</measure>
    <time_frame>Up to 1 year following completion of chemoradiation.</time_frame>
    <description>Effect of treatment assignment on tumor outcomes (locoregional failure, distant metastases, progression-free survival, overall survival) Only 73 subjects in Placebo Arm were analyzed for locoregional failure, distant disease and progression-free survival because 1 subject was determined after enrollment to have a non-head and neck cancer and was therefore excluded from these analyses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Radiation Induced Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Low Dose GC4419: 30mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg GC4419/day prior to IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose GC4419: 90mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg GC4419/day prior to IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily, prior to IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose GC4419: 30mg/day</intervention_name>
    <description>Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).</description>
    <arm_group_label>Low Dose GC4419: 30mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose GC4419: 90mg/day</intervention_name>
    <description>High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).</description>
    <arm_group_label>High Dose GC4419: 90mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks</description>
    <arm_group_label>High Dose GC4419: 90mg/day</arm_group_label>
    <arm_group_label>Low Dose GC4419: 30mg/day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
    <arm_group_label>High Dose GC4419: 90mg/day</arm_group_label>
    <arm_group_label>Low Dose GC4419: 30mg/day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck,&#xD;
             defined as SCC of the oral cavity or oropharynx that will be treated with cisplatin&#xD;
             plus concurrent IMRT Note: Patients with unknown primary tumors whose treatment plan&#xD;
             matches the requirements specified in Inclusion Criteria #2 and #3 below are eligible&#xD;
             for the trial.&#xD;
&#xD;
          2. Treatment plan to receive a continuous course of IMRT delivered as single daily&#xD;
             fractions of 2.0 to 2.2 Gy with a cumulative radiation dose between 60 Gy and 72 Gy.&#xD;
             Planned radiation treatment fields must include at least two oral sites (buccal&#xD;
             mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total&#xD;
             of &gt; 50 Gy. Patients who have had prior surgery are eligible, provided they have fully&#xD;
             recovered from surgery, and patients who may have surgery in the future are eligible.&#xD;
&#xD;
          3. Treatment plan to receive standard cisplatin monotherapy administered either every&#xD;
             three weeks (80-100 mg/m2 for 3 doses) or weekly (30-40 mg/m2 for 6-7 doses). The&#xD;
             decision on which chemotherapy regimen to use in combination with IMRT and GC4419 will&#xD;
             be at the discretion of the investigator.&#xD;
&#xD;
          4. Age 18 years or older&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          6. Adequate hematologic function as indicated by:&#xD;
&#xD;
               -  Absolute neutrophil counts (ANC) ≥ 1,500/mm3&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          7. Adequate renal and liver function as indicated by:&#xD;
&#xD;
               -  Serum creatinine acceptable for treatment with cisplatin per institutional&#xD;
                  guidelines&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper-normal limit (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
          8. Human papilloma virus (HPV) status in tumor has been documented using tumor&#xD;
             immunohistochemistry for HPV-p16 or other accepted test&#xD;
&#xD;
          9. Serum pregnancy test negative for females of childbearing potential&#xD;
&#xD;
         10. Males and females must agree to use effective contraception starting prior to the&#xD;
             first day of treatment and continuing for 30 days after the last dose of GC4419&#xD;
&#xD;
         11. Properly obtained written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glands&#xD;
&#xD;
          2. Metastatic disease (Stage IV C)&#xD;
&#xD;
          3. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites or&#xD;
             more than 25% of total body marrow-bearing area (potentially interfering with&#xD;
             chemotolerance)&#xD;
&#xD;
          4. Prior induction chemotherapy&#xD;
&#xD;
          5. Receiving any approved or investigational anti-cancer agent other than those provided&#xD;
             for in this study&#xD;
&#xD;
          6. Participation in another clinical trial or use of another investigational agent within&#xD;
             30 days of study entry&#xD;
&#xD;
          7. Requirement for significantly modified diet (liquids and/or solids) due to compromised&#xD;
             oral/pharyngeal function at baseline&#xD;
&#xD;
          8. Requirement at baseline for parenteral or gastrointestinal tube-delivered nutrition&#xD;
             for any reason&#xD;
&#xD;
          9. Malignant tumors other than head and neck cancer (HNC) within the last 5 years, unless&#xD;
             treated definitively and with low risk of recurrence in the judgment of the treating&#xD;
             investigator&#xD;
&#xD;
         10. Active infectious disease excluding oral candidiasis&#xD;
&#xD;
         11. Presence of oral mucositis (World Health Organization Score ≥ Grade 1) at study entry&#xD;
&#xD;
         12. Known history of HIV or active hepatitis B/C (patients who have been vaccinated for&#xD;
             hepatitis B and do not have a history of infection are eligible)&#xD;
&#xD;
         13. Female patients who are pregnant or breastfeeding&#xD;
&#xD;
         14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds&#xD;
&#xD;
         15. Requirement for concurrent treatment with nitrates or other drugs that may, in the&#xD;
             judgment of the treating investigator, create a risk for a precipitous decrease in&#xD;
             blood pressure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon T Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center at Dignity Health St. Joseph's</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fowler Family Center for Cancer Care</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences- Winthrop P. Rockefeller Cancer Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials and Research Associates, Inc.</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Regional Cancer Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UConn Health School of Dental Medicine</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Pinellas Cancer Center</name>
      <address>
        <city>Holiday</city>
        <state>Florida</state>
        <zip>34691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Health Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Oncology Group</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Indianan, Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashland-Bellefonte Cancer Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Albert B. Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital, James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Schumpert Cancer Treatment Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Regional Cancer Program</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Allegiance Health</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Huron Medical Center</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fichel Cancer Center, University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renown Cancer Institute</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunterdon Hematology Oncology, LLC Hunterdon Regional Cancer Center</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center- Hackensack Meridian Health</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University, Leo W. Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marion L. Shepard Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas-Jefferson University Hospital-Bodine Center for Cancer Treatment</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital, Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Health Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Health Care System</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Health Alliance</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>36704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital and Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cancer Centre, Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-centre-du-Québec</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación de Investigación</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <results_first_submitted>May 4, 2021</results_first_submitted>
  <results_first_submitted_qc>August 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <disposition_first_submitted>August 1, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 1, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 9, 2019</disposition_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma of the head and neck</keyword>
  <keyword>oral cavity</keyword>
  <keyword>oropharynx</keyword>
  <keyword>intensity-modulated radiation therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>oral mucositis</keyword>
  <keyword>superoxide dismutase</keyword>
  <keyword>radioprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avasopasem manganese</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02508389/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02508389/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose GC4419: 30mg/Day</title>
          <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="P2">
          <title>High Dose GC4419: 90mg/Day</title>
          <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose GC4419: 30mg/Day</title>
          <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="B2">
          <title>High Dose GC4419: 90mg/Day</title>
          <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="223"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="9.10"/>
                    <measurement group_id="B2" value="57.6" spread="10.6"/>
                    <measurement group_id="B3" value="57.9" spread="9.61"/>
                    <measurement group_id="B4" value="57.7" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria</title>
        <description>Assessed from the first determination of ≥Grade 3 OM to the first instance of non-severe OM (≤Grade 2), without a subsequent instance of ≥Grade 3</description>
        <time_frame>From start of Intensity-modulated radiation therapy (IMRT) through 8 weeks follow-up, an average of 15 weeks</time_frame>
        <population>intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria</title>
          <description>Assessed from the first determination of ≥Grade 3 OM to the first instance of non-severe OM (≤Grade 2), without a subsequent instance of ≥Grade 3</description>
          <population>intent to treat population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0" upper_limit="93"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="19" lower_limit="0" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events</title>
        <description>Number of participants with treatment emergent adverse events (TEAE) per arm</description>
        <time_frame>First dose of IMRT through the completion of IMRT, estimated to be up to 7 weeks.</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events</title>
          <description>Number of participants with treatment emergent adverse events (TEAE) per arm</description>
          <population>Treated Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Subjects with at least one TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at least one serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experience Severe OM</title>
        <description>Number of participants who experience severe OM from the first IMRT fraction through the last IMRT fraction</description>
        <time_frame>Minimum of 60 Gy administered to tumor, approximately 30 IMRT fractions, which is estimated to be 6-7 weeks.</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Severe OM</title>
          <description>Number of participants who experience severe OM from the first IMRT fraction through the last IMRT fraction</description>
          <population>Intent to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Grade 4 OM From the First IMRT Fraction Through the Last IMRT Fraction</title>
        <description>Number of Participants who experienced Grade 4 OM</description>
        <time_frame>First dose of IMRT through the completion of IMRT, estimated to be up to 6-7 weeks.</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Grade 4 OM From the First IMRT Fraction Through the Last IMRT Fraction</title>
          <description>Number of Participants who experienced Grade 4 OM</description>
          <population>Intent to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of IMRT Fractions Delivered at Onset of Severe OM</title>
        <description>Onset of severe OM: number of IMRT fractions delivered at onset of severe OM</description>
        <time_frame>Onset of Severe OM, estimated to be between first dose of IMRT and 7 weeks.</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of IMRT Fractions Delivered at Onset of Severe OM</title>
          <description>Onset of severe OM: number of IMRT fractions delivered at onset of severe OM</description>
          <population>Intent to treat population</population>
          <units>IMRT Fractions</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="25.00" upper_limit="35.00"/>
                    <measurement group_id="O2" value="35" lower_limit="28.00" upper_limit="35.00"/>
                    <measurement group_id="O3" value="28" lower_limit="22.00" upper_limit="33.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Grade 4 Oral Mucocitis (OM) From the First IMRT Fraction Through the Last IMRT Fraction</title>
        <description>Number of Participants who experienced Grade 4 OM</description>
        <time_frame>Onset of Grade 4 OM, estimated to be between first dose of IMRT and 7 weeks.</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Grade 4 Oral Mucocitis (OM) From the First IMRT Fraction Through the Last IMRT Fraction</title>
          <description>Number of Participants who experienced Grade 4 OM</description>
          <population>Intent to Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths</title>
        <description>Effect of treatment assignment on tumor outcomes (locoregional failure, distant metastases, progression-free survival, overall survival) Only 73 subjects in Placebo Arm were analyzed for locoregional failure, distant disease and progression-free survival because 1 subject was determined after enrollment to have a non-head and neck cancer and was therefore excluded from these analyses</description>
        <time_frame>Up to 1 year following completion of chemoradiation.</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose GC4419: 30mg/Day</title>
            <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O2">
            <title>High Dose GC4419: 90mg/Day</title>
            <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths</title>
          <description>Effect of treatment assignment on tumor outcomes (locoregional failure, distant metastases, progression-free survival, overall survival) Only 73 subjects in Placebo Arm were analyzed for locoregional failure, distant disease and progression-free survival because 1 subject was determined after enrollment to have a non-head and neck cancer and was therefore excluded from these analyses</description>
          <population>Intent to treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number With Locoregional Failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number With Distant Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number with Progressive Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Deaths</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from first dose study drug through 30 days after last dose, approximately 11 weeks</time_frame>
      <desc>All-cause mortality was reported for all randomized intent-to-treat subjects (ITT) (inclusive of randomization failures who did not get treated). Adverse Events (AEs)/Serious Adverse Events (SAEs) were analyzed for only subjects who received at least one dose of study drug (treated population)</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose GC4419: 30mg/Day</title>
          <description>30 mg GC4419/day prior to IMRT&#xD;
Low Dose GC4419: 30mg/day: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="E2">
          <title>High Dose GC4419: 90mg/Day</title>
          <description>90 mg GC4419/day prior to IMRT&#xD;
High Dose GC4419: 90mg/day: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo daily, prior to IMRT&#xD;
Placebo: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).&#xD;
Intensity-Modulated Radiation Therapy: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks&#xD;
Cisplatin: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.&#xD;
Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Stoma site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Stoma site pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kara Terry</name_or_title>
      <organization>Galera Therapeutics, Inc.</organization>
      <phone>610-725-1500</phone>
      <email>kterry@galeratx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

